Skip to main content
. 2023 Feb 1;11(2):e005545. doi: 10.1136/jitc-2022-005545

Figure 1.

Figure 1

Single cell spatial landscape of response to ICI in NSCLC. (A) Schematic of IMC acquisition of multiplexed images from 27 patients with NSCLC, involving laser ablation of metal-conjugated antibodies, CyTOF acquisition, single-cell phenotyping and characterization of the prevalence and interactions of immune cells. (B) Cell assignment hierarchy. (C) Representative images of antibody staining and corresponding single-cell segmented images for responders and non-responders. (D) Average expression of markers in indicated cell populations. (E) Kaplan-Meier overall survival analysis for 11 patients with NSCLC treated with ICI (responders n=6, non-responders n=5). (F) Frequency of cancer and immune cell populations in responders and non-responders to immune checkpoint inhibitors as a proportion of total cells. Non-Cl Mo - responders versus non-responders: *p=0.017316. (G) Ratio of average marker intensity in cancer and immune cell populations. Green represents higher intensity in responders, gray in non-responders and white was not calculated. Median±IQR. Statistical analysis (E: log-rank test, F: Mann-Whitney test). Cl Mo, classical monocyte; CyTOF, cytometry by time of flight; DC, dendritic cell; ICI, immune checkpoint inhibitor; IMC, imaging mass cytometry; Int Mo, intermediate monocyte; M1-like MAC, M1-like macrophage; M2-like MAC, M2-like macrophage; NK cell, natural killer cell; Non-Cl Mo, non-classical monocyte; NSCLC, non-small cell lung cancer; Tc, cytotoxic T cell; Th, helper T cell; TMA, tissue microarray; Treg, regulatory T cell.